Sunshine Guojian Pharmaceutical (Shanghai) , Ltd EBIT

The latest EBIT for 688336.SS is $3.4B as of September 2026. That compares with $880M in the prior-year period — up 287.9% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Sunshine Guojian Pharmaceutical (Shanghai) , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 688336.SS's EBIT moved from $880M to $3.4B — a 287.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sunshine Guojian Pharmaceutical (Shanghai) , Ltd's operating scale or balance-sheet position.

Against Healthcare companies, 688336.SS currently prints $3.4B for EBIT, while the sector average sits near $130B. That is roughly 97.5% below the sector mean. Large gaps often invite a closer look at Sunshine Guojian Pharmaceutical (Shanghai) , Ltd's growth, margins, and balance sheet.

A EBIT figure of $3.4B for 688336.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 688336.SS's EBIT ($3.4B), review year-over-year change from $880M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.